Cidara Therapeutics (CDTX): Buy recommendation from H.C. Wainwright with target of $41!
Reading Time: 2 minutes
Cidara Therapeutics (CDTX) has strategically repositioned itself. The company is now exclusively focused on its groundbreaking project CD388. This drug is intended to provide long-term protection against all influenza viruses (Type A and B) – essentially acting as a form of "universal flu protection." CD388 belongs to a new class of compounds known as DFC. This is a combination of a drug and a special part of an antibody that allows the drug to remain effective in the body for a longer period. This combination is based on the company’s proprietary...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
